Latest Breaking News On - Regulatoryt cell - Page 1 : vimarsana.com

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Alireza Faridar, the Stanley H. Appel Chair in Translational.

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

Cell Therapy Startup With Stanford Roots Unveils $75M to Seek Inflammation Cures

Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.

T Cell Subset Promotes Self Recognition, Prevents Autoimmunity + Warning

A subset of regulatory T cells possess memory-like qualities that could help shape immunotherapy development, according to a study published in Science.

How Regulatory T Cells Can Reduce Solid Tumors In Mice

Research on regulatory T cells is building towards a durable and long-lasting treatment for many solid cancers.

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

Regeneron Jumps Into Cell Therapy via Alliance With Treg Startup Sonoma Bio

Regeneron is paying Sonoma Biotherapeutics $75 million to begin a partnership focused on developing cell therapies based on regulatory T cells, or Tregs. Each company brings technological capabilities to the alliance, which is initially focused on ulcerative colitis and Crohn’s disease.

Live-Action 'Cells at Work' Adaptation Announced

Aniplex Japan Reveals 'Cells at Work' Anime Blu-ray Box Set Packaging